# Menstrual Cycle Length Changes Following Vaccination Against Influenza Alone or With COVID-19

Emily R Boniface, Blair G Darney, Agathe van Lamsweerde, Eleonora

Benhar, Alexandra Alvergne, Alison Edelman

► To cite this version:

Emily R Boniface, Blair G Darney, Agathe van Lamsweerde, Eleonora Benhar, Alexandra Alvergne, et al.. Menstrual Cycle Length Changes Following Vaccination Against Influenza Alone or With COVID-19. JAMA Network Open, 2025, 8 (4), pp.e257871. 10.1001/jamanetworkopen.2025.7871. hal-05061964

HAL Id: hal-05061964

https://hal.umontpellier.fr/hal-05061964v1

Submitted on 9 May 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

**Original Investigation** | Obstetrics and Gynecology

# Menstrual Cycle Length Changes Following Vaccination Against Influenza Alone or With COVID-19

Emily R. Boniface, MPH; Blair G. Darney, PhD, MPH; Agathe van Lamsweerde, MSc; Eleonora Benhar, PhD; Alexandra Alvergne, PhD; Alison Edelman, MD, MPH

## Abstract

**IMPORTANCE** Multiple studies have identified an association between COVID-19 vaccination and menstrual disturbances. Data on whether menstrual health is impacted by other vaccines are needed to counsel individuals about what to expect and to address vaccine hesitancy.

**OBJECTIVE** To assess the association of changes in length of the menstrual cycle with influenza vaccination, with or without concurrent receipt of a COVID-19 vaccine.

**DESIGN, SETTING, AND PARTICIPANTS** This global retrospective cohort study prospectively collected menstrual cycle data from April 25, 2023, to February 27, 2024 (4-5 cycles per individual), among international English-speaking users of a digital birth control application. Participants included individuals aged 18 to 45 years, not using hormonal contraception, and with average cycle lengths of 24 to 38 days in 3 consecutive cycles before receipt of vaccines.

**EXPOSURE** Seasonal influenza vaccination with or without concurrent receipt of COVID-19 vaccine.

**MAIN OUTCOME AND MEASURE** The primary outcome consisted of adjusted mean within-individual changes of menstrual cycle length assessed by vaccination group. Secondary analysis evaluated the phase of menstrual cycle at time of vaccination.

**RESULTS** A total of 1501 individuals met the inclusion criteria, of whom 791 were vaccinated for influenza only and 710 were concurrently vaccinated for influenza and COVID-19. By race and ethnicity, 1 participant (0.1%) was American Indian or Alaska Native; 10 (0.7%), Asian; 3 (0.2%), Black; 15 (1.0%), Hispanic or Latina; 1 (0.1%), Middle Eastern or North African; 368 (24.5%), White; and 19 (1.3%), other; and 1084 (72.2%), missing. Most of the cohort was younger than 35 years (1230 [82.0%]), had at least a college degree (1122 [74.8%]), and was located in the US or Canada (938 [62.5%]). Individuals vaccinated for influenza alone experienced an adjusted mean increase of 0.40 (95% CI, 0.08-0.72) days, while those vaccinated concurrently for influenza and COVID-19 experienced a mean increase of 0.49 (95% CI, 0.16-0.83) days (P = .69 for difference between vaccine groups). A total of 37 individuals (4.7%) experienced a change in cycle length of at least 8 days with influenza vaccine only and 42 (5.9%) with concurrent receipt of both vaccines (P = .28). In the postvaccination cycle, both vaccination groups returned to their prevaccination cycle lengths. Menstrual cycle changes occurred with vaccination in the follicular phase but not the luteal phase.

**CONCLUSIONS AND RELEVANCE** In this cohort study of individuals with regular menstrual cycles, influenza vaccine given alone or in combination with a COVID-19 vaccine was associated with a small but temporary change in menstrual cycle length. These findings may help clinicians confirm the utility of vaccination for patients with concerns about menstrual adverse effects of vaccination.

## Key Points

**Question** Is the influenza vaccine alone or with a COVID-19 vaccine associated with change in menstrual cycle length?

**Findings** In this cohort study of 1501 participants, in individuals with regular menstrual cycles, a temporary small but statistically significant increase in menstrual cycle length (<1 day) with receipt of an influenza vaccine, with or without a COVID-19 vaccine, based on vaccination in the follicular phase was found.

**Meaning** These findings may help to confirm the utility of vaccination for individuals with concerns about adverse effects of vaccination on menstruation.

## + Supplemental content

Author affiliations and article information are listed at the end of this article.

JAMA Network Open. 2025;8(4):e257871. doi:10.1001/jamanetworkopen.2025.7871

<figure><img src="image_3.png" /></figure>

**Open Access.** This is an open access article distributed under the terms of the CC-BY License.
## Introduction

In January 2019, the World Health Organization recognized vaccine hesitancy as one of the top 10 threats to global health.¹ The public's concerns about vaccines and their adverse effects can directly impact vaccine hesitancy and impede the uptake of vaccines, which in turn increases rates of preventable disease.²⁻⁴ Reported menstrual changes following receipt of the COVID-19 vaccine received a substantial amount of attention and concern from civil society and the media, which impacted uptake.⁵ However, establishment of a link between vaccines and menstrual changes is not new. For example, the Japanese government was forced to suspend their human papillomavirus (HPV) vaccine program in 2013 following reports of adverse effects including menstrual cycle disturbances in adolescents and young women, which raised fears of potential impacts on future fertility.⁶ Initial uptake was 70%, but following these reports, vaccination uptake plummeted to less than 1% among the eligible population.⁷⁻⁹ The absence of data to directly address anecdotal reports has had long-lasting impacts: uptake of HPV vaccine is still low in Japan, and HPV vaccine programs in other countries were also shown to be negatively impacted.¹⁰⁻¹² More importantly, the lack of HPV vaccine uptake is estimated to result in approximately 10 000 preventable deaths from cervical cancer in Japan in the next 50 years.¹³

Prior work from some of the investigators from the present study and others¹⁴⁻¹⁷ has found a small temporary change in menstrual cycle length and heaviness in menstrual flow for individuals receiving the COVID-19 vaccine, particularly for those who are vaccinated during the follicular phase of the menstrual cycle. While the underlying mechanisms behind this finding are not fully understood, we have known for several decades that the immune and reproductive systems interact closely with one another, but the interaction does not cause infertility.¹⁸ An individual's response to a vaccine is impacted by a variety of factors, including prior exposure to the disease and/or vaccine, immunogenicity of the vaccine, time from either event, and biological sex, among others.¹⁹,²⁰ Despite the potential for menstrual cycle disturbances following vaccination, menstrual health outcomes have been overlooked in prior vaccine clinical trials, creating a critical knowledge gap about these important preventative health tools.¹⁶

Influenza is a long-standing common endemic virus. Influenza vaccination is the best way to prevent or decrease complications of influenza and is recommended annually to offset waning immunity. Now that COVID-19 infection has transitioned from pandemic to endemic, we appear to be moving into an annual vaccination schedule that will include recommendations to receive both influenza and COVID-19 vaccines. However, any potential impact of influenza vaccination on menstrual cycle changes and whether those changes may differ with concurrent receipt of the COVID-19 vaccine remain unknown. Herein we analyze prospectively collected menstrual cycle data among those who received the influenza vaccine alone or on the same day as COVID-19 vaccination. We compare changes in menstrual cycle length in days and the prevalence of clinically meaningful changes (≥8 days) between vaccination groups,²¹ in both the vaccination and postvaccination cycles.

## Methods

### Data Source

This retrospective cohort study used prospectively collected menstrual cycle data from a digital birth control application (Natural Cycles; Nordic AB). Individuals use the application to plan or prevent pregnancy without the use of hormonal contraceptive methods; details about the variables collected by the application have been published previously.²² To be eligible for study inclusion, individuals needed to consent to the use of their deidentified data for research purposes, be aged 18 to 45 years, and respond to an in-application message about receipt and timing of a seasonal influenza and/or COVID-19 vaccination in August 2023 or later. Retrospective self-reported data on vaccination timing were then paired with prospectively collected data on menstrual cycles. We excluded individuals
who indicated that they had received at least 1 vaccination but did not provide a vaccination date, only received COVID-19 vaccine, received both vaccines but in different cycles or different days within the same cycle, had no data for the vaccination cycle or fewer than 3 prevaccination cycles, had nonconsecutive cycles, had a mean prevaccination cycle length outside the reference range of 24 to 38 days,²¹ were at least 38 days into the vaccination cycle prior to receiving a vaccine, self-identified as menopausal, or were less than 3 cycles after pregnancy or after hormonal contraception use for the entire study period (Figure 1). The Institutional Review Board of the Oregon Health & Science University, Portland, approved the protocol and did not require informed written consent beyond an introduction to the brief survey and a reminder regarding the revocable consent to the use of deidentified data for research purposes provided by users within the application. This report follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

Cycle data in the final analytical sample ranged between April 25, 2023, and February 27, 2024; vaccines were received from August 21, 2023, to January 29, 2024. Each individual contributed data from a minimum of 4 consecutive cycles: 3 prevaccination cycles and the cycle in which they received their vaccines (vaccination cycle). We also included data from a fifth cycle immediately following the vaccination cycle (postvaccination cycle) if available. If data from the postvaccination cycle were not available, we excluded those individuals (n = 30) from postvaccination cycle analyses.

Our primary binary independent variable was vaccination group: receipt of an influenza vaccine only or concurrent receipt of both influenza and COVID-19 vaccines on the same day. We chose to focus on these study groups since completely naive (unvaccinated) individuals are rare in the study population. Our primary outcome was the adjusted within-individual change in menstrual cycle length (in days) from the mean of the 3 prevaccination cycles to the vaccination cycle; each individual therefore served as their own control. We also assessed the change in cycle length from the prevaccination cycle mean to the postvaccination cycle, and whether the vaccination or postvaccination change in cycle length was clinically meaningful (defined as a change of ≥8 days).²¹

We included several sociodemographic characteristics collected within the birth control application. We categorized age into approximate 5-year groups: 18 to 24, 25 to 29, 30 to 34, 35 to 39, and 40 to 45 years. Individuals reported their race and ethnicity using options defined by the application as American Indian or Alaska Native, Asian, Black, Hispanic or Latina, Middle Eastern or North African, White, or other group. We reported racial and ethnic categories to characterize this sample population but did not include these data in our primary adjusted model. We used categorical

<figure><img src="image_4.png" /><figcaption>Figure 1. Sample Flow Diagram</figcaption></figure>

<figure><img src="image_5.png" /></figure>
variables for body mass index (BMI; calculated as the weight in kilograms divided by the height in meters squared): underweight (<18.5), normal weight (18.5-24.9), overweight (25.0-29.9), and obesity (≥30.0). We classified geographic location as the UK and Channel Islands, continental Europe, US and Canada, and other regions. We also used binary variables to characterize parity (nulliparous vs parous), educational level (less than a college degree vs college degree or more), and relationship status (in a relationship vs not in a relationship). Notably, the birth control application's sociodemographic data collection patterns have changed over time, and report of many sociodemographic variables is optional within the application, which resulted in a large degree of missingness for several variables.

## Statistical Analysis

We compared all sociodemographic characteristics by vaccination group using a Pearson $\chi^2$ or Fisher exact test. We calculated the change in cycle length from the prevaccination mean to the vaccination and postvaccination cycles (excluding 30 individuals with no data for the postvaccination cycle) and adjusted the estimates using linear regression models with change in cycle length as the outcome, vaccination group as the primary independent variable, and age group, BMI category, and parity as adjusting covariates. We then graphed the mean marginal change in cycle length from the models with 95% CIs for individuals who only received the influenza vaccine and those who received both the influenza and COVID-19 vaccine on the same day. We used multiple imputation by chained equations²³ with 50 rounds of imputation to address missingness in adjusting covariates. Data missingness was a function of changes to demographic data collection by the application and considered missing at random. We compared the percentage of individuals who experienced a clinically meaningful change in cycle length (≥8 days) during the vaccination cycle across vaccination groups using a Pearson $\chi^2$ test. We then repeated this analysis for the postvaccination cycle among those who had experienced a clinically meaningful change in cycle length during the prior vaccination cycle.

In addition to assessing unadjusted changes in cycle length, we conducted several sensitivity analyses to confirm the robustness of our results for both the vaccination and postvaccination cycles. First, we excluded any individuals who reported polycystic ovary syndrome, thyroid disorder, or endometriosis (n = 145). Second, we excluded anyone who reported use of emergency contraception in any cycle during the study period (n = 58). Third, we excluded anyone with at least 1 prevaccination cycle outside the 24- to 38-day range (n = 247). Fourth, we developed multivariable models with additional adjusting covariates: race and ethnicity (collapsed to White compared with some other group due to sample size), global region (collapsed to US and Canada compared with other regions), educational level, and relationship status. Finally, we assessed the adjusted change in cycle length based on the menstrual phase timing of vaccination for both vaccination groups: receipt of vaccines in the follicular phase (first day of the cycle through the day of ovulation as estimated by the application's validated algorithm) or luteal phase (day after ovulation through the last day of the cycle), using methods described previously.²⁴ All analyses were conducted using Stata, version 17.0 (StataCorp LLC), and 2-sided P ≤ .05 indicated statistical significance.

## Results

Among the 1501 individuals in this analytical cohort, 1230 (82.0%) were younger than 35 years; 1122 (74.8%) had at least a college degree; and 938 (62.5%) were located in the US or Canada (Table 1). By race and ethnicity, 1 participant (0.1%) was American Indian or Alaska Native; 10 (0.7%), Asian; 3 (0.2%), Black; 15 (1.0%), Hispanic or Latina; 1 (0.1%), Middle Eastern or North African; 368 (24.5%), White; and 19 (1.3%), other; and 1084 (72.2%), missing. Figure 1 summarizes participant flow. The study sample included 791 individuals vaccinated for influenza only and 710 vaccinated for both influenza and COVID-19 on the same day, representing a total of 7475 cycles, with 30 individuals missing data from the postvaccination cycle. Compared with those who received only the influenza

<figure><img src="image_6.png" /></figure>
vaccine, individuals who received both vaccines were more likely to be older than 30 years (391 [55.1%] vs 346 [43.7%]; *P* < .001) and more likely to be located in the US or Canada (511 [72.0%] vs 427 [54.0%]; *P* < .001). All missing data are tabulated in Table 1.

Both vaccination groups experienced a small but statistically significant adjusted increase in cycle length during the vaccination cycle (Figure 2A). Individuals vaccinated for influenza alone experienced a mean increase of 0.40 (95% CI, 0.08-0.72) days, while those vaccinated concurrently for influenza and COVID-19 experienced a mean increase of 0.49 (95% CI, 0.16-0.83) days (*P* = .69 for difference between vaccine groups). In the postvaccination cycle, neither group experienced cycle lengths that were significantly different from those in their prevaccination period (Figure 2B). The adjusted mean change in cycle length was -0.02 (95% CI, -0.31 to 0.27) days for the influenza

<table><caption>Table 1. Characteristics of Study Participants</caption><thead><tr><th rowspan="2">Characteristic</th><th colspan="3">Vaccine group, No. (%)</th><th rowspan="2">P value</th></tr><tr><th>Influenza only (n = 791)</th><th>Influenza and COVID-19 (n = 710)</th><th>All (N = 1501)</th></tr></thead><tbody><tr><td>Age, y</td><td></td><td></td><td></td><td></td></tr><tr><td>18-24</td><td>147 (18.6)</td><td>70 (9.9)</td><td>217 (14.5)</td><td rowspan="5">&lt;.001</td></tr><tr><td>25-29</td><td>298 (37.7)</td><td>249 (35.1)</td><td>547 (36.4)</td></tr><tr><td>30-34</td><td>211 (26.7)</td><td>255 (35.9)</td><td>466 (31.0)</td></tr><tr><td>35-39</td><td>108 (13.7)</td><td>111 (15.6)</td><td>219 (14.6)</td></tr><tr><td>40-45</td><td>27 (3.4)</td><td>25 (3.5)</td><td>52 (3.5)</td></tr><tr><td>Race and ethnicity</td><td></td><td></td><td></td><td></td></tr><tr><td>American Indian or Alaska Native</td><td>1 (0.1)</td><td>0</td><td>1 (0.1)</td><td rowspan="7">.01</td></tr><tr><td>Asian</td><td>5 (0.6)</td><td>5 (0.7)</td><td>10 (0.7)</td></tr><tr><td>Black</td><td>2 (0.3)</td><td>1 (0.1)</td><td>3 (0.2)</td></tr><tr><td>Hispanic or Latina</td><td>7 (0.9)</td><td>8 (1.1)</td><td>15 (1.0)</td></tr><tr><td>Middle Eastern or North African</td><td>1 (0.1)</td><td>0</td><td>1 (0.1)</td></tr><tr><td>White</td><td>174 (22.0)</td><td>194 (27.3)</td><td>368 (24.5)</td></tr><tr><td>Some other race<sup>a</sup></td><td>11 (1.4)</td><td>8 (1.1)</td><td>19 (1.3)</td></tr><tr><td>Missing</td><td>590 (74.6)</td><td>494 (69.6)</td><td>1084 (72.2)</td><td></td></tr><tr><td>Parity</td><td></td><td></td><td></td><td></td></tr><tr><td>Nulliparous</td><td>214 (27.1)</td><td>245 (34.5)</td><td>459 (30.6)</td><td rowspan="3">.003</td></tr><tr><td>Parous</td><td>34 (4.3)</td><td>19 (2.7)</td><td>53 (3.5)</td></tr><tr><td>Missing</td><td>543 (68.6)</td><td>446 (62.8)</td><td>989 (65.9)</td></tr><tr><td>BMI</td><td></td><td></td><td></td><td></td></tr><tr><td>Underweight (&lt;18.5)</td><td>17 (2.1)</td><td>10 (1.4)</td><td>27 (1.8)</td><td rowspan="5">.12</td></tr><tr><td>Normal weight (18.5-24.9)</td><td>325 (41.1)</td><td>282 (39.7)</td><td>607 (40.4)</td></tr><tr><td>Overweight (25.0-29.9)</td><td>165 (20.9)</td><td>122 (17.2)</td><td>287 (19.1)</td></tr><tr><td>Obesity (≥30.0)</td><td>81 (10.2)</td><td>80 (11.3)</td><td>161 (10.7)</td></tr><tr><td>Missing</td><td>203 (25.7)</td><td>216 (30.4)</td><td>419 (27.9)</td></tr><tr><td>Educational level</td><td></td><td></td><td></td><td></td></tr><tr><td>Less than college degree</td><td>61 (7.7)</td><td>31 (4.4)</td><td>92 (6.1)</td><td rowspan="3">.02</td></tr><tr><td>College degree or more</td><td>589 (74.5)</td><td>533 (75.1)</td><td>1122 (74.8)</td></tr><tr><td>Missing</td><td>141 (17.8)</td><td>146 (20.6)</td><td>287 (19.1)</td></tr><tr><td>Relationship status</td><td></td><td></td><td></td><td></td></tr><tr><td>Not in relationship</td><td>32 (4.0)</td><td>34 (4.8)</td><td>66 (4.4)</td><td rowspan="3">.03</td></tr><tr><td>In relationship</td><td>214 (27.1)</td><td>233 (32.8)</td><td>447 (29.8)</td></tr><tr><td>Missing</td><td>545 (68.9)</td><td>443 (62.4)</td><td>988 (65.8)</td></tr><tr><td>Geographic region</td><td></td><td></td><td></td><td></td></tr><tr><td>UK and Channel Islands</td><td>266 (33.6)</td><td>168 (23.7)</td><td>434 (28.9)</td><td rowspan="5">&lt;.001</td></tr><tr><td>Europe</td><td>96 (12.1)</td><td>30 (4.2)</td><td>126 (8.4)</td></tr><tr><td>US and Canada</td><td>427 (54.0)</td><td>511 (72.0)</td><td>938 (62.5)</td></tr><tr><td>Other</td><td>2 (0.3)</td><td>1 (0.1)</td><td>3 (0.2)</td></tr></tbody></table>

Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared).

<figure><img src="image_7.png" /></figure>

<footnote>a Individuals in this category selected "other" when reporting their race and ethnicity within the application; no additional data are available regarding their racial and ethnic identities.</footnote>
only group and 0.14 (95% CI, -0.17 to 0.45) days for the influenza and COVID-19 group (P = .46 for the between-group difference). eTable 1 in Supplement 1 includes summary statistics for cycle lengths and changes from prevaccination mean.

During the vaccination cycle, the percentage of individuals who experienced a clinically meaningful change in cycle length of 8 days or more was slightly higher in the group that received both vaccines concurrently compared with influenza only (42 of 710 [5.9%] vs 37 of 791 [4.7%]) (Table 2), but the difference was not statistically significant (P = .28). Among those who experienced a clinically meaningful change in cycle length during the vaccination cycle (≥8 days), there were no statistically significant differences in the percentage who continued to experience a clinically meaningful change in the postvaccination cycle between the vaccination groups (10 of 36 [27.8%] for influenza only vs 8 of 39 [20.5%] for both vaccines; P = .46).

Our sensitivity analyses excluding individuals with polycystic ovary syndrome, thyroid disorder, or endometriosis, individuals reporting emergency contraception use, or individuals with any prevaccination cycle lengths outside the normal range or adjusting for the full set of covariates did not alter our findings in a meaningful way, with the exception that the change in vaccination cycle length for individuals vaccinated for influenza alone was not statistically significant after excluding those with self-reported gynecological or thyroid disorders (eTable 2 in Supplement 1). However, in that sensitivity analysis, the cycle length change was significant for individuals who received both vaccines with an increase of 0.53 (95% CI, 0.21 to 0.86) days.

When we examined the adjusted change in cycle length in both vaccination groups by the menstrual phase of vaccination, only individuals who were vaccinated in the follicular phase experienced a statistically significant increase in cycle length compared with their prevaccination mean length: increase of 0.82 (95% CI, 0.40-1.24) days for influenza alone and 0.99 (95% CI, 0.55-1.43) days for concurrent influenza and COVID-19 vaccines (Figure 3A). Individuals vaccinated in the luteal phase experienced no change in cycle length: -0.16 (95% CI, -0.63 to 0.32) days for influenza alone vs -0.14 (95% CI, -0.64 to 0.36) days for both vaccines. In the postvaccination cycle, no groups experienced a significant change in cycle length regardless of menstrual phase of vaccination or vaccines received (Figure 3B).

<figure><img src="image_8.png" /><figcaption>Figure 2. Adjusted Change in Menstrual Cycle Length by Vaccination Group</figcaption></figure>

Change in cycle length was calculated as the difference, in days, from the prevaccination mean cycle length to the vaccination cycle (N = 1501) and the postvaccination cycle (n = 1471). Individuals were vaccinated for influenza alone or influenza concurrently with COVID-19. Estimates were adjusted for age group, body mass index category, and parity following multiple imputation for missing data. Error bars represent 95% CIs; the dotted horizontal line at 0 indicates no change from the prevaccination period.

<table><caption>Table 2. Percentage of Individuals Experiencing a Change in Cycle Length of 8 Days of More From the Mean Prevaccination to Vaccination Cycles or Postvaccination Cycle</caption><thead><tr><th rowspan="2">Cycle</th><th rowspan="2">Outcome</th><th colspan="2">Vaccination group, No./total No. (%)</th><th rowspan="2">P value</th></tr><tr><th>Influenza only</th><th>Influenza and COVID-19</th></tr></thead><tbody><tr><td>Vaccination</td><td>≥8 d Change</td><td>37/791 (4.7)</td><td>42/710 (5.9)</td><td>.28</td></tr><tr><td>Postvaccination</td><td>≥8 d Change<sup>a</sup></td><td>10/36 (27.8)</td><td>8/39 (20.5)</td><td>.46</td></tr></tbody></table>

<footnote>a Among individuals with the clinically meaningful change in cycle length (≥8 days) in the vaccination cycle. Individuals with no data available for the postvaccination cycle (n = 4) were excluded from postvaccination cycle tabulations.</footnote>
Discussion

Misinformation and the dearth of data to confirm or refute the vaccine experience can decrease acceptability and uptake of a vaccine. Prior work including investigators from the present study<sup>14,15</sup> found that the COVID-19 vaccine temporarily lengthens the menstrual cycle by about 1 day or less, while a small subset of individuals will experience a clinically meaningful cycle length change of 8 days or more. In the present cohort study, we found a similarly temporary small increase in cycle length for individuals receiving seasonal influenza vaccine only or influenza plus COVID-19 vaccine, based on vaccination during the follicular phase, and a small subset who experienced a cycle length change of 8 days or more. This provides an important first data point about how influenza vaccination might affect menstrual cyclicity, a topic that has been largely ignored throughout the almost century-long history of influenza vaccines.

A substantial amount of one's lifetime is spent menstruating. It is a common routine bodily function occurring for approximately 1 week each month for 40 years. While the COVID-19 pandemic brought many challenges, it did highlight the lack of evidence on this important patient-oriented outcome. Public concern about new vaccines creates mistrust about all vaccines. We have seen a recent decline in overall vaccination uptake.²⁵ We hypothesized that given the endemic nature of influenza and the widespread exposure to the influenza vaccine, we might not see any signal, but given that vaccines are meant to cause an immune response each time they are received, it is also not surprising that our findings are similar to those for the COVID-19 vaccine. Notably, our findings also suggest that concurrent administration of the COVID-19 vaccine with influenza vaccination does not appear to significantly increase the risk of menstrual cycle disturbances, which may help clinicians confirm the utility of vaccination with these temporary changes and help improve vaccine uptake rates for both endemic diseases.

The increase in cycle length we observed appears to be based on individuals vaccinated in the follicular phase of their menstrual cycle. This is in line with previous work from some of the investigators of the present study,²⁴ which found an approximately 1-day increase in cycle length for individuals vaccinated for COVID-19 during the follicular phase, but no change for those vaccinated in the luteal phase or for an unvaccinated control group. Our results support the current hypothesis that the immune response triggered by vaccination temporarily impacts the hypothalamic-pituitary-ovarian axis, although it is unclear whether this is a series of temporary responses or 1 primary change and at what level of the axis this occurs.²⁴,²⁶,²⁷ Individuals who are concerned about potential menstrual cycle disturbances following vaccination for influenza and/or COVID-19 could

<figure><img src="image_9.png" /><figcaption>Figure 3. Adjusted Change in Menstrual Cycle Length, by Vaccination Group and Menstrual Phase of Vaccination</figcaption></figure>

Change in cycle length was calculated as the difference in days from the prevaccination mean cycle length to the vaccination cycle and the postvaccination cycle, by vaccination group and timing of vaccination (follicular vs luteal phase). Individuals were vaccinated for influenza alone (457 in the follicular phase and 334 in the luteal phase) or influenza and COVID-19 concurrently (395 in the follicular phase and 315 in the luteal phase). Estimates were adjusted for age group, body mass index category, and parity following multiple imputation for missing data. Error bars represent 95% CIs; the dotted horizontal line at 0 indicates no change from the prevaccination period.

<figure><img src="image_10.png" /></figure>
consider timing their vaccination to coincide with their luteal phase to minimize their risk of cycle length changes.

While small changes in menstrual health may not seem meaningful to many clinicians and scientists, any perceived impact in a routine bodily function linked to fertility can cause alarm and contribute to vaccine hesitancy. To draw a parallel, this might be comparable to whether reports of temporary erectile dysfunction occurred post vaccination, which is by no means a serious adverse event but is a cause of distress if unanticipated, potentially raising concerns for future fertility, and which could certainly fuel vaccine hesitancy. While sporadic deviations from menstrual norms are not cause for clinical concern, they can have a large adverse impact on the quality of life during menstruation for individuals who experience episodes of social embarrassment, anxiety related to uncontained bleeding or pregnancy, and worry about what bleeding changes mean for their overall health and fertility.²⁸⁻³⁰ Any change, even if small and not clinically relevant, is important to the public, and even more so in the context of vaccines and rampant misinformation.³¹

## Strengths and Limitations

The strengths of our study include a large global sample of prospectively collected menstrual cycle data before, during, and after self-confirmed vaccine timing and type. Menstrual cycles are known to be inherently variable, but we attempted to mitigate this by using data from individuals not using hormonal contraception with proven regular cycles prior to vaccination as their own controls and excluding individuals with known irregular cycles.

This study also has some limitations. First, our dataset had high levels of missingness for several sociodemographic characteristics, potentially limiting our ability to address confounding. However, various approaches to multiple imputation did not change our findings. Second, our sample is largely White, nulliparous, and highly educated and has a low BMI, which could limit the generalizability of our results. Third, we were only able to adjust for sociodemographic characteristics collected by the application; our estimates may be affected by residual confounding. Fourth, vaccination dates were self-reported and may be subject to recall bias, but we conducted the survey during the most active time of influenza vaccination. We also excluded a large proportion of eligible individuals who did not have enough cycle data to adequately assess our outcome. This is due to the fact that the user base for the birth control application has grown over time, and newer users were not yet tracking their cycle data around the time of vaccination. Prior work¹⁴,¹⁵,¹⁷,²⁴ compared COVID-19 vaccinated individuals with an unvaccinated control group; in this study we compare receipt of influenza vaccine alone or in combination with COVID-19 vaccine, which represents a common clinical scenario. Individuals truly naive to either vaccine are rare; both influenza and the influenza vaccine have been endemic for decades.

## Conclusions

In this cohort study, we found that receipt of influenza vaccine alone and receipt of both influenza and COVID-19 on the same day were associated with small (<1 day) changes in menstrual cycle length, based on vaccination during the follicular phase. We further showed no differences by vaccination group in the proportion of individuals who experience a clinically meaningful (≥8 days) change in cycle length. Our findings can confirm that concurrent receipt of influenza and COVID-19 vaccines does not appear to be associated with large menstrual cycle changes in most people.

## ARTICLE INFORMATION

**Accepted for Publication:** February 28, 2025.

**Published:** April 29, 2025. doi:10.1001/jamanetworkopen.2025.7871

<figure><img src="image_11.png" /></figure>
**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](https://creativecommons.org/licenses/by/4.0/). © 2025 Boniface ER et al. *JAMA Network Open*.

**Corresponding Author:** Alison Edelman, MD, MPH, Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson, Mail Code UHN 50, Portland, OR 97239 (edelmana@ohsu.edu).

**Author Affiliations:** Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland (Boniface, Darney, Edelman); OHSU-PSU (Oregon Health & Science University-Portland State University) School of Public Health, Portland (Boniface, Darney); Instituto Nacional de Salud Pública, Centro de Investigación en Salud Poblacional, Cuernavaca, México (Darney); Natural Cycles Nordic AB, Stockholm, Sweden (van Lamsweerde, Benhar); Institut des Sciences de l'Evolution de Montpellier, Montpellier University, Centre National de la Recherche Scientifique, Institut de Recherche pour le Développement, Montpellier, France (Alvergne); School of Anthropology and Museum Ethnography, University of Oxford, Oxford, UK (Alvergne).

**Author Contributions:** Ms Boniface had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Boniface, Darney, Alvergne, Edelman.

**Acquisition, analysis, or interpretation of data:** Boniface, Darney, van Lamsweerde, Benhar, Edelman.

**Drafting of the manuscript:** Boniface, Edelman.

**Critical review of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Boniface, Darney.

**Obtained funding:** Edelman.

**Administrative, technical, or material support:** van Lamsweerde, Edelman.

**Supervision:** Darney, Benhar, Alvergne, Edelman.

**Conflict of Interest Disclosures:** Dr Darney reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study, an honorarium from the American College of Obstetricians and Gynecologists, and nonfinancial support from Society of Family Planning travel expenses outside the submitted work and serving as deputy editor at *Contraception*. Ms van Lamsweerde reported receiving personal fees from Natural Cycles Nordic AB during the conduct of the study. Dr Benhar reported receiving personal fees from Natural Cycles Nordic AB during the conduct of the study. Dr Edelman reported receiving grant support from the NIH during the conduct of the study and receiving royalties from Contemporary Forums and UpToDate Inc, research sponsorship to institution from Organon & Co and HRA Pharma, honoraria for continuing medical education activities from Medscape, honoraria for advisory group participation from FHI 360, grant support from the Gates Foundation, and travel reimbursement for advisory group activities from the World Health Organization and Centers for Disease Control and Prevention outside the submitted work. No other disclosures were reported.

**Funding/Support:** This study was supported by grant NICHD089957 from the US National Institute of Child Health and Human Development (principal investigator, Dr Edelman).

**Role of the Funder/Sponsor:** The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement:** See Supplement 2.

REFERENCES

1. World Health Organization. Ten threats to global health in 2019. Accessed January 30, 2022. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

2. Lane S, MacDonald NE, Marti M, Dumolard L. Vaccine hesitancy around the globe: analysis of three years of WHO/UNICEF joint reporting form data—2015-2017. Vaccine. 2018;36(26):3861-3867. doi:10.1016/j.vaccine.2018.03.063

3. European Commission Directorate General for Health and Food Safety. State of vaccine confidence in the EU 2018. 2018. Accessed January 30, 2022. https://op.europa.eu/en/publication-detail/-/publication/678e38ae-a154-11ea-9d2d-01aa75ed71a1/language-en

4. Kunitoki K, Funato M, Mitsunami M, Kinoshita T, Reich MR. Access to HPV vaccination in Japan: increasing social trust to regain vaccine confidence. Vaccine. 2021;39(41):6104-6110. doi:10.1016/j.vaccine.2021.08.085

5. Hamel L, Lopes L, Sparks G, et al. KFF COVID-19 vaccine monitor: October 2021. Accessed January 30, 2022. https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-october-2021/

6. Larson HJ, Wilson R, Hanley S, Parys A, Paterson P. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation. *Hum Vaccin Immunother*. 2014;10(9):2543-2550. doi:10.4161/21645515.2014.969618

<figure><img src="image_12.png" /></figure>
7. Tozawa-Ono A, Kamada M, Teramoto K, et al. Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study. *Hum Vaccin Immunother*. 2021;17(4):950-954. doi:10.1080/21645515.2020.1817715

8. Ikeda SI, Hineno A, Ozawa K, Kinoshita T. Suspected adverse effects after human papillomavirus vaccination: a temporal relationship. *Immunol Res*. 2018;66(6):723-725. doi:10.1007/s12026-018-9063-y

9. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. *Papillomavirus Res*. 2018;5:96-103. doi:10.1016/j.pvr.2018.02.002

10. Sekine M, Kudo R, Yamaguchi M, et al. Japan's ongoing crisis on HPV vaccination. *Vaccines (Basel)*. 2020;8(3):E362. doi:10.3390/vaccines8030362

11. Suppli CH, Hansen ND, Rasmussen M, Valentiner-Branth P, Krause TG, Mølbak K. Decline in HPV-vaccination uptake in Denmark—the association between HPV-related media coverage and HPV-vaccination. *BMC Public Health*. 2018;18(1):1360. doi:10.1186/s12889-018-6268-x

12. Simas C, Munoz N, Arregoces L, Larson HJ. HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia. *Hum Vaccin Immunother*. 2019;15(1):163-166. doi:10.1080/21645515.2018.1511667

13. Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. *Lancet Public Health*. 2020;5(4):e223-e234. doi:10.1016/S2468-2667(20)30010-4

14. Edelman A, Boniface ER, Male V, et al. Association between menstrual cycle length and COVID-19 vaccination: global, retrospective cohort study of prospectively collected data. *BMJ Med*. 2022;1(1):e000297. doi:10.1136/bmjmed-2022-000297

15. Edelman A, Boniface ER, Benhar E, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a US cohort. *Obstet Gynecol*. 2022;139(4):481-489. doi:10.1097/AOG.0000000000004695

16. Payne LA, Wise LA, Wesselink AK, Wang S, Missmer SA, Edelman A. Association between COVID-19 vaccination and menstruation: a state of the science review. *BMJ Sex Reprod Health*. 2024;50(3):212-225. doi:10.1136/bmjsrh-2024-202274

17. Darney BG, Boniface ER, Van Lamsweerde A, et al. Impact of coronavirus disease 2019 (COVID-19) vaccination on menstrual bleeding quantity: An observational cohort study. *BJOG*. 2023;130(7):803-812. doi:10.1111/1471-0528.17471

18. Zaçe D, La Gatta E, Petrella L, Di Pietro ML. The impact of COVID-19 vaccines on fertility—a systematic review and meta-analysis. *Vaccine*. 2022;40(42):6023-6034. doi:10.1016/j.vaccine.2022.09.019

19. Binici B, Rattray Z, Schroeder A, Perrie Y. The role of biological sex in pre-clinical (mouse) mRNA vaccine studies. *Vaccines (Basel)*. 2024;12(3):282. doi:10.3390/vaccines12030282

20. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16(10):626-638. doi:10.1038/nri.2016.90

21. Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. *Int J Gynaecol Obstet*. 2018;143(3):393-408. doi:10.1002/ijgo.12666

22. Bull JR, Rowland SP, Scherwitzl EB, Scherwitzl R, Danielsson KG, Harper J. Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. *NPJ Digit Med*. 2019;2(1):83. doi:10.1038/s41746-019-0152-7

23. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? *Int J Methods Psychiatr Res*. 2011;20(1):40-49. doi:10.1002/mpr.329

24. Edelman A, Boniface ER, Male V, et al. Timing of coronavirus disease 2019 (COVID-19) vaccination and effects on menstrual cycle changes. *Obstet Gynecol*. 2024;143(4):585-594. doi:10.1097/AOG.00000000000005550

25. Cunniff L, Alyanak E, Fix A, et al. The impact of the COVID-19 pandemic on vaccination uptake in the United States and strategies to recover and improve vaccination rates: a review. *Hum Vaccin Immunother*. 2023;19(2):2246502. doi:10.1080/21645515.2023.2246502

26. Male V. COVID-19 vaccination and menstruation. *Science*. 2022;378(6621):704-706. doi:10.1126/science.ade1051

27. Bar-Joseph H, Raz Y, Eldar-Boock A, et al. The direct effect of SARS-CoV-2 virus vaccination on human ovarian granulosa cells explains menstrual irregularities. *NPJ Vaccines*. 2024;9(1):117. doi:10.1038/s41541-024-00911-2

<figure><img src="image_13.png" /></figure>
28. Matteson KA, Clark MA. Questioning our questions: do frequently asked questions adequately cover the aspects of women's lives most affected by abnormal uterine bleeding? opinions of women with abnormal uterine bleeding participating in focus group discussions. *Women Health*. 2010;50(2):195-211. doi:10.1080/03630241003705037

29. Sveinsdóttir H. Menstruation, objectification and health-related quality of life: a questionnaire study. *J Clin Nurs*. 2018;27(3-4):e503-e513. doi:10.1111/jocn.14049

30. Gatny H, Kusunoki Y, Barber J. Pregnancy scares and change in contraceptive use. *Contraception*. 2018;98(4):260-265. doi:10.1016/j.contraception.2018.07.134

31. Muric G, Wu Y, Ferrara E. COVID-19 vaccine hesitancy on social media: building a public Twitter data set of antivaccine content, vaccine misinformation, and conspiracies. *JMIR Public Health Surveill*. 2021;7(11):e30642. doi:10.2196/30642

SUPPLEMENT 1.

eTable 1. Summary Statistics for Change in Cycle Length for Vaccination and Postvaccination Cycles, Overall and by Vaccination Group

eTable 2. Sensitivity Analyses for the Primary Outcome of the Change in Cycle Length, in Days, From the Prevaccination Mean to the Vaccination and Postvaccination Cycles, by Vaccination Status

SUPPLEMENT 2.

Data Sharing Statement

<figure><img src="image_14.png" /></figure>